Sumitomo Pharma Drug Patent Portfolio
Sumitomo Pharma owns 2 orange book drugs protected by 13 US patents Given below is the list of Sumitomo Pharma's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11793812 | Methods of treating endometriosis | 03 May, 2038 | Active |
| US11033551 | Methods of treating uterine fibroids | 29 Sep, 2037 | Active |
| US11957684 | Treatment of heavy menstrual bleeding associated with uterine fibroids | 29 Sep, 2037 | Active |
| US10449191 | Treatment of prostate cancer | 29 Sep, 2037 | Active |
| US10786501 | Treatment of prostate cancer | 29 Sep, 2037 | Active |
| US11583526 | Treatment of prostate cancer | 29 Sep, 2037 | Active |
| US12097198 | Treatment of prostate cancer | 29 Sep, 2037 | Active |
| US10350170 | Solid preparation | 25 Feb, 2036 | Active |
| US11795178 | Compositions of thienopyrimidine derivatives | 27 Sep, 2033 | Active |
| US7300935 | Thienopyrimidine compounds and use thereof | 28 Jan, 2025 | Active |
| US8058280 | Substituted thieno[2,3-d]pyrimidin-2,4-dione compounds and uses thereof | 28 Jan, 2025 | Active |
| US9346822 | Thienopyrimidine compounds and use thereof | 17 Feb, 2024 | Expired |
| US8735401 | Thienopyrimidine compounds and use thereof | 04 Feb, 2024 | Expired |
Latest Legal Activities on Sumitomo Pharma's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Sumitomo Pharma.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Email Notification
Critical
| 09 Jul, 2024 | US10786501 |
| Mail Patent eCofC Notification | 09 Jul, 2024 | US10786501 |
| Recordation of Patent eCertificate of Correction | 09 Jul, 2024 | US10786501 |
| Patent eCofC Notification | 09 Jul, 2024 | US10786501 |
| Mail Certificate of Correction Memo | 02 Jul, 2024 | US11583526 |
| Mail Certificate of Correction Memo | 02 Jul, 2024 | US10449191 |
| Post Issue Communication - Certificate of Correction | 01 Jul, 2024 | US11583526 |
| Post Issue Communication - Certificate of Correction | 01 Jul, 2024 | US10449191 |
| Certificate of Correction Memo | 30 Jun, 2024 | US11583526 |
| Certificate of Correction Memo | 30 Jun, 2024 | US10449191 |
| Post Issue Communication - Certificate of Correction | 17 Jun, 2024 | US10786501 |
| Mail Certificate of Correction Memo | 12 Jun, 2024 | US10786501 |
| Certificate of Correction Memo | 07 Jun, 2024 | US10786501 |
|
Email Notification
Critical
| 17 Apr, 2024 | US11957684 |
| Recordation of Patent eGrant | 16 Apr, 2024 | US11957684 |
Sumitomo Pharma Drug Patents' Oppositions Filed in EPO
Sumitomo Pharma drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Dec 15, 2022, by Sandoz Ag. This opposition was filed on patent number EP17823018A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP17823018A | Dec, 2022 | SANDOZ AG | Granted and Under Opposition |
Sumitomo Pharma's Family Patents
Sumitomo Pharma Drug List
Given below is the complete list of Sumitomo Pharma's drugs and the patents protecting them.
1. Myfembree
Myfembree is protected by 7 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11793812 | Methods of treating endometriosis |
03 May, 2038
(13 years from now)
| Active |
| US11033551 | Methods of treating uterine fibroids |
29 Sep, 2037
(12 years from now)
| Active |
| US11957684 | Treatment of heavy menstrual bleeding associated with uterine fibroids |
29 Sep, 2037
(12 years from now)
| Active |
| US11795178 | Compositions of thienopyrimidine derivatives |
27 Sep, 2033
(8 years from now)
| Active |
| US7300935 | Thienopyrimidine compounds and use thereof |
28 Jan, 2025
(a month from now)
| Active |
| US8058280 | Substituted thieno[2,3-d]pyrimidin-2,4-dione compounds and uses thereof |
28 Jan, 2025
(a month from now)
| Active |
| US9346822 | Thienopyrimidine compounds and use thereof |
17 Feb, 2024
(10 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Myfembree's drug page
2. Orgovyx
Orgovyx is protected by 9 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10449191 | Treatment of prostate cancer |
29 Sep, 2037
(12 years from now)
| Active |
| US10786501 | Treatment of prostate cancer |
29 Sep, 2037
(12 years from now)
| Active |
| US11583526 | Treatment of prostate cancer |
29 Sep, 2037
(12 years from now)
| Active |
| US12097198 | Treatment of prostate cancer |
29 Sep, 2037
(12 years from now)
| Active |
| US10350170 | Solid preparation |
25 Feb, 2036
(11 years from now)
| Active |
| US11795178 | Compositions of thienopyrimidine derivatives |
27 Sep, 2033
(8 years from now)
| Active |
| US7300935 | Thienopyrimidine compounds and use thereof |
28 Jan, 2025
(a month from now)
| Active |
| US8058280 | Substituted thieno[2,3-d]pyrimidin-2,4-dione compounds and uses thereof |
28 Jan, 2025
(a month from now)
| Active |
| US8735401 | Thienopyrimidine compounds and use thereof |
04 Feb, 2024
(10 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Orgovyx's drug page